Flutamide

3 trials LOncology

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

3 Completed trials

2 Sponsors

11 Countries

Phase III

Phase III: 3

Oversight events:

2 unexpected events across 1 trial

View oversight register →

Indications tested

Prostate cancer 2

Sponsors using this IMP

Cancer Trials Ireland 2 Novartis Pharma AG 1

All trials

3 total

An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended

2023-507970-42-00 Phase III 10 countries Novartis Pharma AG
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET Ended

2024-516137-13-00 Phase III 1 country Cancer Trials Ireland
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostat… Ended

2024-514808-13-00 Phase III 3 countries Cancer Trials Ireland

Showing 1–3 of 3 trials

← All drugs A–Z